SCHEMBL223268

SCHEMBL223268

C=CC(=O)OCCCCCCOc1ccc(C(=O)Oc2ccc(O)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.49
THRB P10828 1/20 0.49
TSHR P16473 2/20 0.49
CYP3A4 P08684 2/20 0.49
ALDH1A1 P00352 2/20 0.49
LMNA P02545 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
NPC1 O15118 2/20 0.48
NFKB1 P19838 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 2/20 0.47
ESR1 P03372 1/20 0.47
MAPK1 P28482 1/20 0.47
NR1H2 P55055 1/20 0.47
RNASEL Q05823 1/20 0.47
CYP2C9 P11712 1/20 0.46
PRSS1 P07477 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12794263 1.00 HTT (0.49) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL14280595 1.00 HTT (0.49) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL12768610 1.00 HTT (0.49) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL12510630 1.00 HTT (0.49) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL8666203 0.99 THRB (0.50) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL22245659 0.99 THRB (0.50) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL14370289 0.99 THRB (0.50) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL17301297 0.99 THRB (0.50) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL711551 0.96 HTT (0.46) HTTTHRBTSHRCYP3A4ALDH1A1
SCHEMBL427272 0.96 THRB (0.50) HTTTHRBTSHRCYP3A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3343285-A1 LIQUID CRYSTAL CELL LG Chem, Ltd. (KR) 2018-07-04 EP disclosed
EP-2698411-B9 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2017-12-06 EP disclosed
EP-2698411-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2017-02-01 EP disclosed
EP-2698412-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2016-10-12 EP disclosed
CN-102112579-B Mesogen-containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-10-29 CN disclosed
EP-2303987-B9 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2014-09-10 EP disclosed
EP-2303987-B1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL INC (US) 2014-03-26 EP disclosed
EP-2698413-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
EP-2698412-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
EP-2698411-A2 Mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2014-02-19 EP disclosed
US-7910020-B2 Liquid crystal compositions comprising mesogen containing compounds TRANSITIONS OPTICAL, INC. (US) 2011-03-22 US disclosed
US-20100014010-A1 FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2010-01-21 US disclosed
US-20090326186-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-31 US disclosed
US-20090323011-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-31 US disclosed
US-20090323012-A1 LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPITCAL, INC. (US) 2009-12-31 US disclosed
WO-2009158483-A1 MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-30 WO disclosed
WO-2009158488-A1 LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS TRANSITIONS OPTICAL, INC. (US) 2009-12-30 WO disclosed
US-6303050-B1 COMPOUNDS OF A DEFINED STRUCTURE CAN BE USED IN A PLANNED MANNER FOR BUILDING UP LIQUID-CRYSTALLINE POLYMERS AND THUS FOR CONTROLLING THE CHARACTERISTICS OF THESE POLYMERS. DAIMLERCHRYSLER AG (DE) 2001-10-16 US disclosed
EP-1015525-A1 DYES WITH OPTICALLY VARIABLE PROPERTIES Clariant GmbH (DE) 2000-07-05 EP disclosed
WO-1999011734-A1 DYES WITH OPTICALLY VARIABLE PROPERTIES CLARIANT GMBH (DE) 1999-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100014010-A1 FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS MYOC, RARG, MTX2 HTT 794/4885THRB 3857/4885TSHR 3245/4885
US-20090326186-A1 MESOGEN CONTAINING COMPOUNDS MYOC, BMP2, RARG HTT 1202/4885THRB 3786/4885TSHR 3521/4885
US-20090323011-A1 MESOGEN CONTAINING COMPOUNDS MYOC, BMP2, RARG HTT 1202/4885THRB 3786/4885TSHR 3521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.